Abstract
Laboratory and clinical investigation have been carried out on T-1220, a new ampicillin derivative antibiotic, and following results were obtained.
1) Antimicrobial activity of T-1220 against clinically isolated E. coli, Klebsiella pneumoniae, .Proteus and Pseudomonas aeruginosa was more active than that of conventional penicillin derivatives CBPC and SBPC.
2) Clinically, T-1220 was applied to 8 patients with infectious diseases, and 5 out of 8 patients were improved, the efficacy rate being 75.0 percent.
3) T-1220 was found to have neither adverse effect on renal and liver function, nor on the peripheral blood.
4) T-1220 having potent antibacterial activity against Pseudomonas sp. and Klebsiella pneumoniae is considered to be a promising drug especially for urinary and respiratory tract infections.
